Gamida Cell Ltd. – NASDAQ:GMDA

Add to watchlist

Market closed

Open in 37 minutes

-89.47%

month

-88.23%

quarter

-94.78%

year

Market Cap	4.33M
Enterprise value	87.70M

P/E	-0.62
EV/Sales	N/A
EV/EBITDA	-2.42
Price/Sales	N/A
Price/Book	-5.82
PEG ratio	4.40
EPS	-0.25

Revenue	N/A
EBITDA	-31.19M
Income	-22.09M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Gamida Cell Ltd. (NASDAQ:GMDA): Profit margin
Jun 2023	0	-31.67M
Sep 2023	673K	-1.51M	-225.71%
Dec 2023	1.11M	-8.84M	-795.77%
Mar 2024	890K	19.94M	2241.12%

Gamida Cell Ltd. Financials Estimate

Q Y

Gamida Cell Ltd. (NASDAQ:GMDA): Analyst Estimates
2027	727.2M	242.10M	33.29%

Analysts Price target
Financials & Ratios estimates

Gamida Cell Ltd. (NASDAQ:GMDA): Earnings per share (EPS)
2022-11-14	-0.27483	-0.29
2023-03-27	-0.25	-0.3
2023-05-15	-0.27	-0.27

Gamida Cell Ltd. (NASDAQ:GMDA): Debt to assets
Jun 2023	112508000	138.22M	122.85%
Sep 2023	117748000	117.36M	99.68%
Dec 2023	102186000	105.13M	102.89%
Mar 2024	79558000	98.28M	123.54%

Gamida Cell Ltd. (NASDAQ:GMDA): Cash Flow
Jun 2023	-22.00M	6K	29.44M
Sep 2023	-18.57M	282K	24.50M
Dec 2023	-15.46M	-259.56K	2.29M
Mar 2024	-22.99M	-89K	1.33M

Gamida Cell Ltd. alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Gamida Cell Ltd. (NASDAQ:GMDA): Employee count
Aug 2023	143
Sep 2023	143
Oct 2023	143
Nov 2023	143
Dec 2023	143
Jan 2024	143
Feb 2024	143
Mar 2024	143
Apr 2024	143
May 2024	143
Jun 2024	143
Jul 2024	143

Gamida Cell Ltd.
Hedge Funds Holdings Q1 2023

28.33% -9.14%

of GMDA is owned by hedge funds

34 -18

hedge funds hold GMDA stock

18.08M -4.56M

shares is hold by hedge funds

GMDA hedge funds holdings changes

Gamida Cell Ltd.
Insider Trading

Gamida Cell Ltd. (NASDAQ:GMDA): Insider trades (number of shares)
Period	Buy	Sel
Sep 2022	85483	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	30 Sep 2022	WILLS STEPHEN T director director	Ordinary Shares	9,677	$1.55	$14,999
Purchase	30 Sep 2022	BLUM ROBERT I director	Ordinary Shares	50,000	$1.55	$77,500
Purchase	30 Sep 2022	TOMASELLO SHAWN director director	Ordinary Shares	9,677	$1.55	$14,999
Purchase	30 Sep 2022	JENKINS ABIGAIL L. director, officer: President and CEO director, officer: President an..	Ordinary Shares	16,129	$1.55	$25,000

GMDA insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application EXPANDED NK CELL FRACTIONS FOR TRANSPLANTATION IN COMBINATION THERAPY Filling date: 19 Mar 2020 Issue date: 11 Aug 2022	19 Mar 2020	11 Aug 2022
Application	Application METHOD OF HOMING AND RETENTION OF GAMMADELTA T CELLS, OPTIONALLY WITH NATURAL KILLER CELLS, FOR GENERATING CELL COMPOSITIONS FOR USE IN THERAPY Filling date: 24 Feb 2020 Issue date: 12 May 2022	24 Feb 2020	12 May 2022
Application	Application EXPANSION AND USE OF EXPANDED NK CELL FRACTIONS Filling date: 27 Sep 2018 Issue date: 20 Aug 2020	27 Sep 2018	20 Aug 2020
Application	Application SELECTION AND USE OF UMBILICAL CORD CELL FRACTIONS SUITABLE FOR TRANSPLANTATION Filling date: 16 May 2017 Issue date: 4 Jun 2020	16 May 2017	4 Jun 2020
Application	Application SELECTION AND USE OF UMBILICAL CORD CELL FRACTIONS SUITABLE FOR TRANSPLANTATION Filling date: 16 May 2018 Issue date: 7 May 2020	16 May 2018	7 May 2020

Gamida Cell Ltd.
Earnings Call Transcripts

Quarter	Transcript
Q3 2023 14 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 14 Aug 2023	Q2 2023 Earnings Call Transcript
Q1 2023 15 May 2023	Q1 2023 Earnings Call Transcript
Q4 2023 27 Mar 2023	Q4 2023 Earnings Call Transcript

GMDA earnings call transcripts

Gamida Cell Ltd.
Executives

Insider	Age	Compensation
Dr. Julian Adams Ph.D. (1955) Chief Executive Officer & Director	70	$718,000
Dr. Ronit Simantov M.D. (1965) Chief Medical Officer	60	$560,000
Mr. Joshua D. Hamermesh MBA (1972) Chief Bus. Officer	53	$494,000
Dr. Jas Uppal (1968) Chief Regulatory & Quality Officer	57	$487,000
Mr. Shai Lankry CPA, M.B.A. (1976) Chief Financial Officer	49	$325,000

Gamida Cell Ltd.
Latest News

Friday, 21 June 2024
16:04	On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development	globenewswire.com
Tuesday, 18 June 2024
08:00	Gamida Cell Announces New Leadership Under Ownership of Highbridge Capital Management	businesswire.com
Wednesday, 27 March 2024
11:16	Why Is Gamida Cell (GMDA) Stock Down 82% Today?	InvestorPlace
Friday, 22 March 2024
08:00	Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results	GlobeNewsWire
Wednesday, 17 January 2024
08:00	Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®	GlobeNewsWire
Monday, 20 November 2023
08:00	Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference	GlobeNewsWire
Monday, 9 October 2023
08:53	These Israeli pharmaceutical stocks are down in the wake of Hamas attack	Market Watch
Monday, 14 August 2023
19:02	Gamida Cell: The Treacherous Path To Profitability	Seeking Alpha
Friday, 9 June 2023
10:57	Gamida Cell (GMDA)'s Technical Outlook is Bright After Key Golden Cross	Zacks Investment Research
Wednesday, 31 May 2023
16:30	Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference	Business Wire
Monday, 15 May 2023
20:39	Gamida Cell Ltd. (GMDA) Q1 2023 Earnings Call Transcript	Seeking Alpha
Thursday, 11 May 2023
17:20	Gamida Cell Announces the Date of Its First Quarter 2023 Financial Results and Webcast	Business Wire
Wednesday, 10 May 2023
12:47	Penny Stocks To Buy Now? 3 To Watch In The Stock Market Today	PennyStocks
Wednesday, 19 April 2023
09:01	Why Is Gamida Cell (GMDA) Stock Down 19% Today?	InvestorPlace
Tuesday, 18 April 2023
13:10	Gamida Cell Stock Jumps Over 100% on FDA Approval	MarketBeat
12:13	Gamida Cell shares jump on FDA recognition of allogeneic cell therapy	Proactive Investors
09:26	Why Is Gamida Cell (GMDA) Stock Up 48% Today?	InvestorPlace
08:17	Promising Upsides on these Biotech Penny Stocks	MarketBeat
Monday, 17 April 2023
15:24	3 Hot Penny Stocks To Watch In The Stock Market Today	PennyStocks
Monday, 16 January 2023
13:33	Gamida Cell (GMDA) Upgraded to Buy: Here's Why	Zacks Investment Research
Wednesday, 23 November 2022
08:00	Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences	Business Wire
Monday, 14 November 2022
11:08	Gamida Cell Ltd. (GMDA)Q3 2022 Earnings Call Transcript	Seeking Alpha
Monday, 10 October 2022
07:00	Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa	Business Wire
Monday, 15 August 2022
13:54	Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q2 2022 Results - Earnings Call Transcript	Seeking Alpha
Wednesday, 1 June 2022
16:30	Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference	Business Wire
Tuesday, 17 May 2022
16:30	Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference	Business Wire
Tuesday, 10 May 2022
11:26	Gamida Cell Ltd. (GMDA) Management on Q1 2022 Results - Earnings Call Transcript	Seeking Alpha
Wednesday, 27 April 2022
12:41	Gamida Cell Posts Updated Omidubicel Data In Blood Cancer Patients	Benzinga
Tuesday, 26 April 2022
09:33	Gamida Cell Shares Jump On FDA Nod To Cell Therapy Trial In Blood Cancer Settings	Benzinga
08:58	5 Hot Penny Stocks To Watch With Premarket Momentum & News	PennyStocks

Ideas & Opinions

Seeking Alpha 14 Aug 2023

Gamida Cell: The Treacherous Path To Profitability
Seeking Alpha 6 Oct 2022

Athersys: Is Big Pharma Sleeping At The Wheel?

Frequently Asked Questions (FAQ)

When is Gamida Cell Ltd.'s next earnings date?

Unfortunately, Gamida Cell Ltd.'s (GMDA) next earnings date is currently unknown.
Does Gamida Cell Ltd. pay dividends?

No, Gamida Cell Ltd. does not pay dividends.
How much money does Gamida Cell Ltd. make?

Gamida Cell Ltd. has a market capitalization of 4.33M. Gamida Cell Ltd. made a loss 63M US dollars in net income (profit) last year or -$0.27 on an earnings per share basis.
What is Gamida Cell Ltd.'s stock symbol?

Gamida Cell Ltd. is traded on the NASDAQ under the ticker symbol "GMDA".
What is Gamida Cell Ltd.'s primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Gamida Cell Ltd.?

Shares of Gamida Cell Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Gamida Cell Ltd.'s key executives?
Gamida Cell Ltd.'s management team includes the following people:
- Dr. Julian Adams Ph.D. Chief Executive Officer & Director(age: 70, pay: $718,000)
- Dr. Ronit Simantov M.D. Chief Medical Officer(age: 60, pay: $560,000)
- Mr. Joshua D. Hamermesh MBA Chief Bus. Officer(age: 53, pay: $494,000)
- Dr. Jas Uppal Chief Regulatory & Quality Officer(age: 57, pay: $487,000)
- Mr. Shai Lankry CPA, M.B.A. Chief Financial Officer(age: 49, pay: $325,000)
How many employees does Gamida Cell Ltd. have?

As Jul 2024, Gamida Cell Ltd. employs 143 workers.
When Gamida Cell Ltd. went public?

Gamida Cell Ltd. is publicly traded company for more then 6 years since IPO on 26 Oct 2018.
What is Gamida Cell Ltd.'s official website?

The official website for Gamida Cell Ltd. is gamida-cell.com.
How can i contact Gamida Cell Ltd.?

Gamida Cell Ltd. can be reached via phone at +972 2 659 5666.

Gamida Cell Ltd.

gamida-cell.com

Exchange:

NASDAQ

Full time employees:

143

Industry:

Biotechnology

Sector:

Healthcare

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

+972 2 659 5666

5 Nahum Heftsadie Street
Jerusalem, 91340

CIK: 0001600847
ISIN: IL0011552663
CUSIP: M47364100